These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35526173)

  • 1. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.
    McEwan P; Baker-Knight J; Ásbjörnsdóttir B; Yi Y; Fox A; Wyn R
    Eur J Health Econ; 2023 Mar; 24(2):187-196. PubMed ID: 35526173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens.
    Chancellor J; Aballéa S; Lawrence A; Sheldon R; Cure S; Plun-Favreau J; Marchant N
    Pharmacoeconomics; 2008; 26(3):217-34. PubMed ID: 18282016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
    Matza LS; Cutts KN; Stewart KD; Norrbacka K; García-Pérez LE; Boye KS
    Qual Life Res; 2021 Jul; 30(7):2033-2043. PubMed ID: 33886044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
    Boye K; Ross M; Mody R; Konig M; Gelhorn H
    Diabetes Obes Metab; 2021 Feb; 23(2):508-519. PubMed ID: 33140575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
    Boye KS; Stein D; Matza LS; Jordan J; Yu R; Norrbacka K; Hassan SW; García-Pérez LE
    Drugs R D; 2019 Jun; 19(2):213-225. PubMed ID: 31115873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
    Weeda ER; Muraoka AK; Brock MD; Cannon JM
    Int J Clin Pract; 2021 Sep; 75(9):e14060. PubMed ID: 33527605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilities for treatment-related adverse events in type 2 diabetes.
    Shingler S; Fordham B; Evans M; Schroeder M; Thompson G; Dewilde S; Lloyd AJ
    J Med Econ; 2015 Jan; 18(1):45-55. PubMed ID: 25266815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
    Lau DCW; Batterham RL; le Roux CW
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.